ReviewExpert review of molecular diagnostics2020
Cystatin C as a biomarker of chronic kidney disease: latest developments.
Review in Expert review of molecular diagnostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- The Role of Cystatin C in the Prediction of Contrast-Induced Acute Kidney Injury Following Coronary Procedures: A Systematic Review.Reviews in cardiovascular medicine · 2025Pooled it
- Saliva urea nitrogen for detection of kidney disease in adults: A meta-analysis of diagnostic test accuracy.PloS one · 2025Pooled it
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nature medicine · 2024Trial
- Novel associations of Claudin gene variants with kidney stone disease.Clinical kidney journal · 2026Article
- Modernizing renal eligibility in oncology trials.Lancet regional health. Americas · 2026Article
- Self-Contained Lateral-Flow Microfluidic Bead-Based Assay for Rapid Quantification of Early-Stage Kidney Biomarkers.Analytical chemistry · 2026Article
- Article
- The application of shear wave elastography in monitoring renal allografts.Quantitative imaging in medicine and surgery · 2026Article
- Association of Homocysteine with Arterial Stiffness and Kidney Injury Biomarkers in Patients with Suspected Coronary Artery Disease.Journal of clinical medicine · 2026Article
- Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Persistent nausea burden at peak antiemetic therapy in palliative care: an exploratory study.BMC palliative care · 2026Article
- Leveraging Multiomic Signatures to Predict Body Composition.Advances in nutrition (Bethesda, Md.) · 2026Review
- Cystatin C as a Renal Biomarker in Infants with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT): A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Renal Biomarkers of Injury as Early Predictors of COVID-19 Associated Acute Kidney Injury: A Prospective Observational Trial (BRICOAKI Study).Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2026Article
- The CCR/WC ratio as a predictor of dyslipidemia and Its mediating effect on hypertension in middle-aged and older adults.BMC cardiovascular disorders · 2026Article
- Role of cystatin C in predicting the risk of hypermethotrexemia and kidney injury after high-dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.Annals of hematology · 2026Article
- Study of Cystatin C and Renal Resistive Index in Type 2 Diabetes Mellitus Patients to Detect Early Diabetic Kidney Disease.Annals of African medicine · 2026Article
- Urinary nephrin as an early biomarker of podocyte dysfunction in essential hypertension: a stage-stratified study from Bukhara, Uzbekistan.Frontiers in cardiovascular medicine · 2026Article
- Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
introductionChronic kidney disease (CKD) is common, occurring in over 10% of individuals globally, and is increasing in prevalence. The limitations of traditional biomarkers of renal dysfunction, such as serum creatinine, have been well demonstrated in the literature. Therefore, augmenting clinical assessment with newer biomarkers, such as serum cystatin C, has the potential to improve disease monitoring and patient care. AREAS COVERED: The present paper assesses the utility and limitations of serum cystatin C as a biomarker for CKD in light of the current literature. EXPERT OPINION: Serum cystatin C has been well established as an early and accurate biomarker of CKD that is particularly helpful in patients for whom creatinine is an inadequate marker or for whom more cumbersome methods of glomerular filtration rate (GFR) measurement are impractical. Current research questions are no longer focused on if, but rather when and how often cystatin C should be used in the evaluation of CKD patients. However, transition of all reagents and estimated GFR equations to the newly established International Standard is critical for developing generalizable data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.